£74,928
Recorded Innovate UK grant offers across two closed project records.
Impact.
Public value, with outcomes kept honest.
This page distinguishes documented inputs from outcomes that have not been established. The current public record supports company, project, funding and assurance facts.
It does not yet establish deployment, adoption, clinical validation or public benefit. Those gaps remain visible by design.
Verified inputs and records.
These are source-linked inputs and status records. They are not presented as proof of customer adoption, clinical effect or wider public impact.
2 projects
PHARMORIS and VIONIX ZERO in the UKRI Gateway to Research.
Standards met
NEUVIOR’s 2025–26 NHS DSP Toolkit submission; not an NHS endorsement.
Closed records
The PHARMORIS and VIONIX ZERO UKRI records are closed. Their existence documents funded project activity, not a current programme or achieved outcome.
Outcomes not yet established.
The distinction below is deliberate: a public input can be verified without proving that a product or programme has created impact.
Deployment and adoption
PHARMORIS is under controlled, non-production development. No customer, live deployment or production readiness is claimed.
Clinical or NHS outcome
The DSP Toolkit publication is an assurance record, not NHS endorsement, clinical validation or evidence of product deployment.
VIONIX ZERO continuation
The public record relates to completed feasibility work. It is not presented as an active manufacturing or trials programme.
Absence of an outcome claim is a status boundary, not a prediction about future results.
The public-value agenda.
This is a direction for work, not evidence that the intended effect has already been achieved.
Proposed direction
Make the next action more accountable.
The agenda is to help medicines teams connect identifiable evidence, authorised decisions and visible follow-through. Software may organise evidence and options; accountable people retain judgement and approval.
Future programmes advance only when evidence earns the next gate. That protects public value by keeping focus, responsibility and uncertainty visible.
Evidence before theatre.
A claim should survive a sceptical reader, a source check and the passage of time.
Human authority stays visible.
Software may organise evidence and options; accountable people retain judgement and approval.
Focus funds ambition.
NEUVIOR and PHARMORIS come first. Future theses advance only when evidence earns the next gate.
Unknown remains unknown.
Uncertainty is not a branding flaw. Making it visible protects decisions, partners and reputation.
What must be proved next.
Impact should only enter the public record when the evidence is proportionate to the claim. These are the principal gaps still to close.
A named live setting
Verifiable deployment evidence, with an accountable organisation and a clear description of what is actually in use.
Documented use
Evidence of real workflow use and authorised adoption, separated from a founder statement, demo or development milestone.
A defined outcome method
A stated baseline, measurement method, observation period and source before any benefit or system effect is reported.
Claim-appropriate review
Independent, clinical, regulatory or assurance evidence proportionate to the specific public claim being made.
This is an evidence agenda. It does not confirm that any of these gates has been met.